Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report

Chimeric antigen receptor (CAR)-modified T-cells targeting CD19 represent a promising therapy for relapsed or refractory (r/r) lymphoma and leukemia. The most common adverse events are immune related and include cytokine release syndrome and neurotoxicity. However, early and late hematological toxic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Baur, Rebecca, Jitschin, Regina, Kharboutli, Soraya, Stoll, Andrej, Völkl, Simon, Büttner-Herold, Maike, Schmidt, Daniela, Rösler, Wolf, Mackensen, Andreas, Mougiakakos, Dimitrios
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2021
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8287610/
https://ncbi.nlm.nih.gov/pubmed/34272307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002721
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares